Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
20/10/2012
20/10/2012
2010
|
Resumo |
In a recent study, we demonstrated the immunogenic properties of a new malaria vaccine polypeptide based on a 19 kDa C-terminal fragment of the merozoite surface protein-1 (MSP1(19)) from Plasmodium vivax and an innate immunity agonist, the Salmonella enterica serovar Typhimurium flagellin (FliC). Herein, we tested whether the same strategy, based on the MSP1(19) component of the deadly malaria parasite Plasmodium falciparum, could also generate a fusion polypeptide with enhanced immunogenicity. The His(6)FliC-MSP1(19) fusion protein was expressed from a recombinant Escherichia coil and showed preserved in vitro TLR5-binding activity. In contrast to animals injected with His(6)MSP1(19), mice subcutaneously immunised with the recombinant His6FliC-MSP1(19) developed strong MSP1(19)-specific systemic antibody responses with a prevailing IgG1 subclass. Incorporation of other adjuvants, such as CpG ODN 1826, complete and incomplete Freund`s adjuvants or Quil-A, improved the IgG responses after the second, but not the third, immunising dose. It also resulted in a more balanced IgG subclass response, as evaluated by the IgG1/IgG2c ratio, and higher cell-mediated immune response, as determined by the detection of antigen-specific interferon-gamma secretion by immune spleen cells. MSP(19)-specific antibodies recognised not only the recombinant protein, but also the native protein expressed on the surface of P. falciparum parasites. Finally, sera from rabbits immunised with the fusion protein alone inhibited the in vitro growth of three different P. falciparum strains. In summary, these results extend our previous observations and further demonstrate that fusion of the innate immunity agonist FliC to Plasmodium antigens is a promising alternative to improve their immunogenicity. (c) 2010 Elsevier Ltd. All rights reserved. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Millennium Institute for Vaccine Development and Technology[CNPq 420067/2005-1] Millennium Institute for Vaccine Development and Technology National Institute for Vaccine Development and Technology (CNPq - INCTV) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Rede de Malaria (CNPq) FAPESP Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) |
Identificador |
VACCINE, v.28, n.16, p.2818-2826, 2010 0264-410X http://producao.usp.br/handle/BDPI/28422 10.1016/j.vaccine.2010.02.004 |
Idioma(s) |
eng |
Publicador |
ELSEVIER SCI LTD |
Relação |
Vaccine |
Direitos |
restrictedAccess Copyright ELSEVIER SCI LTD |
Palavras-Chave | #P. falciparum #Vaccine #Flagellin #TLR5 #TOLL-LIKE RECEPTOR-5 #MALARIA VACCINE #BACTERIAL FLAGELLIN #ADJUVANT ACTIVITY #AOTUS MONKEYS #MONOCLONAL-ANTIBODIES #PROTECTIVE IMMUNITY #ADAPTIVE IMMUNITY #INFLUENZA VACCINE #DNA VACCINE #Immunology #Medicine, Research & Experimental |
Tipo |
article original article publishedVersion |